TYP 4.76% 2.0¢ tryptamine therapeutics limited

Ann: Progress Points To Partnering Readiness, page-9

  1. 131 Posts.
    lightbulb Created with Sketch. 19
    SOPHISTRY?? What a nothing announcement designed to bamboozle the acolytes!

    Who on earth writes this kind of doggerel: "I see2021 as ‘The Year We LEAP’,” said Dr Ian Dixon. A better quote would be that from a famous Aussie rules coach: "At least DO SOMETHING! DO! Don't think, don't hope, do"

    EX1 talks a good game about partnering but have delivered a fat NOTHING. Yet the technology is so hot, right?

    And on the clinical data announced today, these are the questions the smart money is asking:
    1. what happened to the "superseded and terminated" earlier clinical trial. It is not possible to just bury a clinical trial as the company has responsibilities to record and report results such as safety etc. SO LET'S SEE THE DATA!
    2. The PLexoval II trial was supposed to recruit 15 volunteers so what happened there? Why stop the study early? What are we not being told?
    3. Where is the efficacy data? They appear to have the safety data but no efficacy data yet??? Sure. The study involved a "skin punch biopsy" which is a pretty simple wound. Surely the efficacy data has been collected and analysed?
    4. When is the next cap raise? EX1 must be burning mountains of cash, now with offices in Basel, one of the most expensive cities in Europe.
 
watchlist Created with Sketch. Add TYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.